Following the 1995 Audit Commission into the standard of hospital records within the NHS, the UK government invested heavily in information technology. This investment has helped change radically the way in which information on routine clinical care is recorded. Now, James Mackay and Ailsa Taylor of The Doctors Organisation for Clinical Studies based in London, say that, despite technical issues with the original IT technology, the system has accumulated a vast amount of potentially invaluable data.
The coupling of this medical data resource with e-Science technologies built with Medical Research Council funding presents a unique opportunity to carry out large-scale pharmacogenetic studies of drug effectiveness and safety for important diseases, such as cancer.
"Many of the ingredients required to start the process of obtaining new knowledge from routinely collected clinical data are already in place," the researchers explain, "However, the vast majority of clinicians and other health professionals are completely unaware of the potential and what progress might be made in a very short time, rather than waiting decades."
Pharmacogenetics is one of the fastest growing areas of medical research because individuals respond to different drugs in different ways. Tiny variations in a person's genetic make up, known as SNPs, single nucleotide polymorphisms, change the structure of key metabolic enzymes in subtle ways. Such changes mean that not all drugs work in the same way for everyone.
For instance, people with a SNP associated with the liver enzyme cytochrome P450 cannot process the common painkiller paracetamol into its active form in their bodies. This makes the drug totally ineffective in those people. SNPs also exist for the metabolic enzymes and protein receptors associated with chemotherapy drugs for cancer and can have subtle or devastating effects.
Doctors would like to know in advance whether particular patients with different genetic backgrounds or ethnic groups have a SNP associated with inactivity of such drugs. Moreover, the presence of certain SNPs in particular patients can make them more susceptible to a drug's side effects or potentially lead to adverse drug reactions. Knowing in advance how a patient might respond to a drug, would give doctors the opportunity to choose an alternative drug or therapy that is not doomed to failure in those patients.
Mackay and Taylor detail the various known SNPs associated with particular drugs. Variations in the cytochrome P450 that makes paracetamol ineffective for some people, also has an effect on how quickly patients respond to a wide range of antidepressants as well as the anticoagulant warfarin used to prevent clotting in heart patients. The team also explains how more than half of Caucasian HIV/AIDS patients who suffer side-effects caused by the antiviral drug abacavir carry a SNP that affects their white blood cells. Testing for the SNP in advance of prescribing the drug could improve outcomes for many AIDS patients.
There are also several examples of how IT coupled with genetics has allowed medical scientists to home in on particular SNPs associated with a positive response to a drug, such as Glivec in chronic myeloid leukaemia. The researchers suggest that, "The rapidly advancing field of genetics has opened up a number of opportunities in medical research likely to significantly impact future clinical practice, including the prescription of drugs based on a patient's genes." They add, "Opportunities to learn new knowledge from routinely collected clinical data held within NHS databases, are very valuable, and should be encouraged."
Jim Corlett | alfa
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences